One important advantage of this ‘alternate non-CFTR approach’ is that it would benefit all CF patients regardless of genotype, and would potentially be useful for other pathologies in which CFTR has been shown to be downregulated such as COPD. Here, CFTR is linked to chronic obstructive pulmonary disease.